Page 5 - Director Program Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article BILTHOVEN, Netherlands, April 7, 2021 /PRNewswire/  Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine. For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV s mixed with rSp (CovOMV) and the other a vaccine based on OMV s coupled to rSp based on Intravacc s proprietary OMV click technology (CovOMVclick). Control animals received respectively only OMV s or only rSp. On day 35 the mice blood samples were tested for virus neutralizing antibodies. The hamsters were challenged with SARS-CoV-2 on day 42 after blood collection. Over a period of seven days after challenges, thei

Noord hollandMirjam hartmanDinja oosterhoffProgram management at intravaccMelinda gates foundationLifespring life sciences communicationMembrane vesicleDirector program managementJan groenUtrecht science park bilthovenSpring life sciences communicationநூற்த் ஹாலண்ட்மெலிண்டா வாயில்கள் அடித்தளம்ஆயுட்காலம் வாழ்க்கை அறிவியல் தொடர்புஇயக்குனர் ப்ரோக்ர்யாம் மேலாண்மைஜான் இடுப்பு